Literature DB >> 99872

The presence of active C1 (C-1) on peripheral human lymphocytes.

H Kitamura, H Teshima, N K Day.   

Abstract

We have shown that the first component of complement C1 is present in an active form on the surface of washed human peripheral lymphocytes but not on platelets or erythrocytes. This active C1 (C-1) was detected by its ability to transfer to sensitized cells carrying C4, i.e., EAC4, forming EAC-1,4. Active C1 was also able to consume C4. Treatment of these lymphocytes with 0.02 M EDTA removed C-1. EDTA-treated lymphocytes were able to bind exogenous purified human C-1. Comparative studies with sentized erythrocytes (EA) and EDTA treated lymphocytes showed that although fewer molecules of exogenous C1 could bind to the EDTA-treated lymphocytes than to EA, the consumption of C4 by C-1 bound to lymphocytes was significantly higher than that observed with EAC-1. When lymphocytes obtained from 2 patients with chronic lymphocytic leukemia and hypocomplementemia were tested, the release of C1, the C4 consumption and the binding of C-1 to EDTA-treated cells were highly inefficient.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 99872     DOI: 10.1111/j.1423-0410.1978.tb02922.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

1.  Characterization of C1 inhibitor binding to neutrophils.

Authors:  N S Chang; R J Boackle; R W Leu
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Relation of neutrophil alkaline phosphatase activity to Fc IgG receptor development in human blood and bone marrow.

Authors:  C S Scott; R J Cordingley; B E Roberts; A G Bynoe; D Hough
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

3.  Depressed classical complement pathway activities in chronic lymphocytic leukaemia.

Authors:  G Füst; E Czink; D Minh; Z Miszlay; L Varga; S R Hollán
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

4.  Acquired C1 inhibitor deficiency in a case of lymphosarcoma of the spleen. Reversal of complement abnormalities after splenectomy.

Authors:  G Hauptmann; F Petitjean; J M Lang; F Oberling
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

5.  Interaction of human platelets with particle-adherent aggregated IgG: description of the experimental system and role of C1q and monomeric IgG.

Authors:  R S Vollertsen; F C McDuffie; E J Bowie
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.